Impact of long-term treatment with neurotoxic dideoxynucleoside antiretrovirals: Implications for clinical care in resource-limited settings

HIV Medicine

Volumn 9, Issue 9, 2008, Pages 731-737

  Hung, C F ^a   Gibson, S A ^a   Letendre, S L ^a   Lonergan, J T ^a   Marquie beck, J A ^a   Vaida, F ^a   Ellis, Ron J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AIDS; Dideoxynucleoside; HIV; Neuropathy

Indexed keywords

2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; DIDANOSINE; STAVUDINE; ZALCITABINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVELOPING COUNTRY; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOG RANK TEST; LONG TERM CARE; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; NEUROPATHIC PAIN; NEUROTOXICITY; PARESTHESIA; PATIENT CARE; POLYNEUROPATHY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SENSORY NEUROPATHY; UNITED STATES;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DEVELOPING COUNTRIES; DIDEOXYNUCLEOSIDES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PARESTHESIA; POLYNEUROPATHIES; PROSPECTIVE STUDIES; RISK ASSESSMENT; VIRAL LOAD;

EID: 54049115929     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00615.x     Document Type: Article

References (25)

1. Blum AS, Dal Pan GJ, Feinberg J et al. Low-dose zalcitabine-related toxic neuropathy: Frequency, natural history, and risk factors. Neurology 1996; 46: 999-1003.
2. Marra CM, Boutin P, Collier AC. Screening for distal sensory peripheral neuropathy in HIV-infected persons in research and clinical settings. Neurology 1998; 51: 1678-1681.
3. Moyle GJ, Sadler M. Peripheral neuropathy with nucleoside antiretrovirals: Risk factors, incidence and management. Drug Saf 1998; 19: 481-494.
4. Simpson DM, Tagliati M. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 9: 153-161.
5. Cherry CL, McArthur JC, Hoy JF, Wesselingh SL. Nucleoside analogues and neuropathy in the era of HAART. J Clin Virol 2003; 26: 195-207.
6. Dalakas MC, Semino-Mora C, Leon-Monzon M. Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2′3′-dideoxycytidine (ddC). Lab Invest 2001; 81: 1537-1544.
7. Moore RD, Wong WM, Keruly JC, McArthur JC. Incidence of neuropathy in HIV-infected patients on monotherapy vs. those on combination therapy with didanosine, stavudine and hydroxyurea. AIDS 2000; 14: 273-278.
8. Simpson DM, Haidich AB, Schifitto G et al. Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels. AIDS 2002; 16: 407-412.
9. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000; 22: 685-708.
10. Cherry CL, Skolasky RL, Lal L et al. Antiretroviral use and other risks for HIV-associated neuropathies in an international cohort. Neurology 2006; 66: 867-873.
11. Morgello S, Estanislao L, Simpson D et al. HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy: The Manhattan HIV Brain Bank. Arch Neurol 2004; 61: 546-551.
12. Renaud-Thery F, Nguimfack BD, Vitoria M et al. Use of antiretroviral therapy in resource-limited countries in 2006: Distribution and uptake of first- and second-line regimens. AIDS 2007; 21(Suppl. 4): 89-95.
13. Nakagawa M, Maruyama Y, Sugita H, Osame M. Nationwide survey of neurologic manifestations of acquired immunodeficiency syndrome in Japan. Intern Med 1997; 36: 175-178.
14. Robertson K, Kopnisky K, Mielke J et al. Assessment of neuroAIDS in Africa. J Neurovirol 2005; 11(Suppl. 1): 7-16.
15. Wong MH, Robertson K, Nakasujja N et al. Frequency of and risk factors for HIV dementia in an HIV clinic in sub-Saharan Africa. Neurology 2007; 68: 350-355.
16. Zanetti C, Manzano GM, Gabbai AA. The frequency of peripheral neuropathy in a group of HIV-positive patients in Brazil. Arq Neuropsiquiatr 2004; 62: 253-256.
17. Schifitto G, McDermott MP, McArthur JC et al. Markers of immune activation and viral load in HIV-associated sensory neuropathy. Neurology 2005; 64: 842-848.
18. Lichtenstein KA, Armon C, Baron A, Moorman AC, Wood KC, Holmberg SD. Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV Outpatient Study Cohort. Clin Infect Dis 2005; 40: 148-157.
19. Simpson DM, Wolfe DE. Neuromuscular complications of HIV infection and its treatment. AIDS 1991; 5: 917-926.
20. Cherry CL, Wesselingh SL, Lal L, McArthur JC. Evaluation of a clinical screening tool for HIV-associated sensory neuropathies. Neurology 2005; 65: 1778-1781.
21. Hawkins C, Achenbach C, Fryda W, Ngare D, Murphy R. Antiretroviral durability and tolerability in HIV-infected adults living in urban Kenya. J Acquir Immune Defic Syndr 2007; 45: 304-310.
22. Nicholas PK, Kemppainen JK, Canaval GE et al. Symptom management and self-care for peripheral neuropathy in HIV/AIDS. AIDS Care 2007; 19: 179-189.
23. Parry O, Mielke J, Latif AS, Ray S, Levy LF, Siziya S. Peripheral neuropathy in individuals with HIV infection in Zimbabwe. Acta Neurol Scand 1997; 96: 218-222.
24. Kumarasamy N, Vallabhaneni S, Cecelia AJ et al. Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India. J Acquir Immune Defic Syndr 2006; 41: 53-58.
25. Hill A, Ruxrungtham K, Hanvanich M et al. Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother 2007; 8: 679-688.